Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 0.47 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | PLK1 | P53350 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | PRKACA | P17612 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2630046 | 0.92 | — | — | |
| SCHEMBL2630038 | 0.92 | — | — | |
| SCHEMBL2630109 | 0.90 | — | — | |
| SCHEMBL2630066 | 0.90 | — | — | |
| SCHEMBL5635925 | 0.89 | JAK3 (0.42) | JAK2 | |
| SCHEMBL5635534 | 0.89 | JAK3 (0.42) | JAK2 | |
| SCHEMBL5635543 | 0.89 | JAK3 (0.42) | JAK2 | |
| SCHEMBL2630353 | 0.88 | JAK3 (0.55) | JAK2ROCK2ROCK1 | |
| SCHEMBL2630352 | 0.88 | JAK3 (0.55) | JAK2ROCK2ROCK1 | |
| SCHEMBL2630104 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973911-B1 | AZAINDOLES USEFUL FOR THE TREATMENT OF (INTER ALIA) PROLIFERATIVE, CARDIAC, NEURODEGENERATIVE, AUTOIMMUNE OR INFLAMMATORY DISORDERS | VERTEX PHARMA (US) | 2016-01-13 | — | — | EP | disclosed |